Greenfern Industries announces changes with Directors

GENERAL
Fri, Nov 29 2024 04:52 pm

Greenfern Industries Linited (NZX.GFI) announces today the appointment of Stuart Hamilton Cairns as an Independent Non-Executive Director. Stuart is the Co-Founder and former Chair of Manuka Bioscience, one of the largest producers of manuka oils in the East Cape. Stuart has a had an extensive career spanning many decades in investment banking.

‘I am passionate about the prospects in New Zealand biological products and remedies. The global potential for this is immense with regulation changes occurring in many countries’, said Stuart.

Simon McArley will be stepping down from the board after a brief orderly transition which should be on or before the 20th of December.

Simon has been an independent director since 2021. We are very grateful to have had his expertise and input for this extended period of time. During his time at GFI we have successfully raised capital through both wholesale and retail raises and we are very appreciative of the knowledge and efforts Simon brought to the processes.

Simon will be moving permanently out of Auckland at the end of the year.

Chair Marvin Yee said: “On behalf of the board of directors and management I would like to sincerely thank Simon for his contribution and commitment to GFI.”

ENDS

For further information, please contact:

Marvin Yee
Chair, Greenfern Industries Ltd
Ph: 027 255 3288
Email: [email protected]


Announcement PDF


Markets News

NZ sharemarket up 0.3% after three falls
Markets Market close

NZ sharemarket up 0.3% after three falls

The S&P/NZX 50 Index closed at 12,761.35, gaining 37.98 points or 0.3%.

Graham Skellern 11 Dec 2024
Property

Winton 'stands to gain millions': MP

The proposed fast-tracking of Sunfield is 'cronyism', local MP claims.

Maria Slade 11 Dec 2024
Winton 'stands to gain millions': MP
Retail

ForBarr raises Hallenstein Glasson target price 20%

The outlook in the golden country is golden, they say.

Gregor Thompson 11 Dec 2024
ForBarr raises Hallenstein Glasson target price 20%